z-logo
open-access-imgOpen Access
miR-106b suppresses pathological retinal angiogenesis
Author(s) -
Catherine Ménard,
Ariel M. Wilson,
Agnieszka Dejda,
Khalil Miloudi,
François Binet,
Sergio CrespoGarcia,
Célia Parinot,
Frédérique Pilon,
Rachel Juneau,
Elisabeth M. M. A. Andriessen,
Gaëlle Mawambo,
John Paul SanGiovanni,
Vincent De Guire,
Przemysław Sapieha
Publication year - 2020
Publication title -
aging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.473
H-Index - 90
ISSN - 1945-4589
DOI - 10.18632/aging.202404
Subject(s) - retinal , angiogenesis , pathological , neuroscience , medicine , ophthalmology , biology , cancer research , pathology
MicroRNAs are small non-coding RNAs that post-transcriptionally regulate gene expression. We recently demonstrated that levels of miR-106b were significantly decreased in the vitreous and plasma of patients with neovascular age-related macular degeneration (AMD). Here we show that expression of the miR-106b-25 cluster is negatively regulated by the unfolded protein response pathway of protein kinase RNA-like ER kinase (PERK) in a mouse model of neovascular AMD. A reduction in levels of miR-106b triggers vascular growth both in vivo and in vitro by inducing production of pro-angiogenic factors. We demonstrate that therapeutic delivery of miR-106b to the retina with lentiviral vectors protects against aberrant retinal angiogenesis in two distinct mouse models of pathological retinal neovascularization. Results from this study suggest that miRNAs such as miR-106b have the potential to be used as multitarget therapeutics for conditions characterized by pathological retinal angiogenesis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom